Company plans to meet with FDA regarding potential sNDA submission in 1H 2025Call planned today at 8:30 a.m. (ET) to discuss company’s diabetes ...

Taken at the beginning of a meal, the medication dissolves rapidly upon oral inhalation into the lungs and delivers insulin ...

Afrezza (insulin human) Inhalation Powder is a rapid-acting inhaled human insulin indicated to improve glycemic control in adults with diabetes mellitus. Limitations of Use: Not recommended for ...

The Central Drugs Standard Control Organisation (CDSCO) has given Cipla the approval to exclusively distribute and market Afrezza (human insulin) inhalation powder in India, the company said.

India has the 2nd highest burden of diabetes worldwideCDSCO decision follows existing approvals in the U.S.A. and BrazilMannKind expects to ship ...

The Central Drugs Standard Control Organisation (CDSCO) has given Cipla the approval to exclusively distribute and market Afrezza (human insulin) inhalation powder in India, the company said.

in India has approved Afrezza (insulin human) Inhalation Powder in adults. The CDSCO decision follows existing approvals in the United States and Brazil. "Achieving approval for Afrezza in India, a ...